Sanofi

This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children and teens aged 2 to 17 with sickle cell disease, who are at higher risk for serious infections. Researchers will compare PCV21 to a licensed vaccine to see if it is safe and helps the body produce prote…

This study is testing an experimental mRNA vaccine to prevent chlamydia, a common sexually transmitted infection. About 1,560 adults aged 18 to 29 who are at higher risk (e.g., new or multiple partners) will receive either a low, medium, or high dose of the vaccine or a placebo. …

This early-stage study tests the safety and immune response of experimental vaccines for respiratory syncytial virus (RSV) and a type of bird flu (H5N1) in 570 healthy adults aged 18 to 49. Participants will receive different vaccine formulas and be monitored for side effects and…

This study tests a new yellow fever vaccine (vYF) in about 2,440 healthy children aged 9 months to 5 years. Researchers want to see if vYF is as safe and effective at creating antibodies as two existing vaccines. Some children will also get the MMR vaccine at the same time. The s…

This study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3-ye…

This study compares two injectable diabetes treatments—iGlarLixi (a combination insulin and GLP-1 drug) and Gla-100 (a standard insulin)—in Chinese adults with type 2 diabetes whose blood sugar is not well controlled with oral medications. About 678 participants will use a contin…

This study tests a new injectable drug called lunsekimig for adults with asthma that is not well-controlled but who are not yet eligible for current biologic treatments. The goal is to see if it can reduce asthma attacks and improve breathing over about a year. Around 1,147 parti…

This study tests a 14-day IV treatment called teplizumab in 10 Japanese people aged 8 to 34 who have Stage 2 type 1 diabetes. The goal is to see if it can safely delay the disease from getting worse. Teplizumab is already approved in the US for this purpose, and this trial focuse…

This study looks at whether it is safe for males aged 12 and older with severe hemophilia A to switch from their current medicine (emicizumab) to a new one called fitusiran. About 20 participants will be followed for up to 28 months to monitor side effects and blood clotting. The…

This study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms compared to a placebo. Participants will receive the drug or placebo for up to 52 weeks, with an…

This study tests a new drug called SAR445399 for people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. About 144 adults will receive either the drug or a placebo for 32 weeks to see if it reduces abscesses and inflammation. …

This study tracks 350 adults with uncontrolled COPD who are starting dupilumab, a medication that helps control inflammation. Over 24 months, researchers will measure changes in quality of life and monitor for side effects. The goal is to see how well dupilumab works in everyday …

This study tests a daily pill called rilzabrutinib in people aged 10 to 65 with sickle cell disease. The goal is to see if it can lower the number of painful vaso-occlusive crises (VOCs) over 52 weeks. About 192 participants will receive either the drug or a placebo. Those who co…

This study follows 1,000 people with early-stage (Stage 2) Type 1 Diabetes who received teplizumab during regular doctor visits. Researchers want to see how long the treatment delays the onset of full-blown (Stage 3) diabetes and how it affects quality of life. The goal is to und…

This study tests an experimental drug called SAR441566 in about 204 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if different doses can help patients achieve remission (…

This study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed first-line treatment. The goal is to see if the drug can safely raise pla…

This study follows about 100 people with moderate to severe hemophilia A in Taiwan who are starting a preventive treatment called efanesoctocog alfa. Researchers will track joint health, bleeding episodes, and safety over up to 5 years using routine clinic visits and medical reco…

This study tests a medicine called fitusiran in boys aged 1 to under 12 with severe hemophilia A or B, including those whose bodies have developed antibodies that block standard treatments. The goal is to see if regular shots of fitusiran can reduce the number of bleeding episode…

This study tests whether a once-weekly drug called efanesoctocog alfa can reduce swelling in the joints of people with hemophilia A. About 35 participants aged 12 and older with moderate to severe hemophilia and existing joint swelling will receive the drug for 12 months. The mai…

This early-phase study tests an experimental drug called SAR448501 in about 96 adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has not responded to or has returned after at least two prior treatments. The main goals are to check the drug's safety and find th…

This study tests a new medicine called duvakitug for people with moderate to severe ulcerative colitis. Participants who already responded to duvakitug in an earlier study will continue treatment for up to 5 years to see if it safely maintains remission. The goal is to control th…

This study compares a new drug, frexalimab, to the standard drug tacrolimus in adults receiving their first kidney transplant. The goal is to see if frexalimab is better at preventing organ rejection and improving kidney function over 5 years. About 526 participants with low-to-m…

This study tests an experimental drug called SAR445877 in about 542 adults with advanced solid tumors that have spread or can't be removed. The goal is to find safe doses and see if the drug, given alone or with other cancer treatments, can shrink tumors. The trial has two parts:…

This study tests an experimental drug called SAR442970 in adults with moderate to severe Crohn's disease. About 99 participants will receive either the drug or a placebo to see if it can reduce gut inflammation and improve symptoms. The goal is to find a better treatment option f…

This study tests an oral drug called rilzabrutinib for adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system destroys red blood cells, causing fatigue and shortness of breath. About 90 participants will receive either the drug or a placebo for …

This study tests a new drug called amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with other treatments. Participants will receive either the drug or a placebo by injection, while continuing to use topical steroids…

This study tests a new drug called riliprubart against standard IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 160 adults who already use IVIg will receive either riliprubart or IV…

This study tests an experimental drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't responded to standard treatments. The goal is to see if the drug can improve disability scores compared to a placebo over 48 weeks. Par…

This study tests a new injectable drug called lunsekimig in adults aged 40-80 with COPD that is not well controlled and who have a certain type of lung inflammation (eosinophilic). The goal is to see if the drug can reduce the number of moderate-to-severe COPD flare-ups over 48 w…

This study tests an oral drug called belumosudil in adults who have chronic lung rejection (CLAD) at least one year after a double lung transplant. The goal is to see if the drug can slow the decline in lung function compared to a placebo, while participants continue their standa…

This study tests a new medicine, duvakitug, to see if it can help people with moderate to severe ulcerative colitis feel better and reach remission. About 980 adults will receive either the drug or a placebo for up to 12 weeks. The goal is to reduce bowel urgency, bleeding, and i…

This study tests a new drug called rilzabrutinib in 30 adults with Graves' disease, a condition where the thyroid makes too much hormone. The goal is to see if the drug can safely lower thyroid hormone levels and improve symptoms. Participants will take one of two doses for 16 we…

This study is for people with multiple myeloma that has come back or stopped responding to treatment. It tests different combinations of the drug isatuximab with newer agents, with or without dexamethasone, to see which works best. About 258 adults will take part, and the goal is…

This study tests a drug called frexalimab in 192 adults and teens recently diagnosed with type 1 diabetes who are already using insulin. The goal is to see if frexalimab can help preserve the body's ability to produce some insulin, reducing the amount of insulin needed long-term.…

This study tests a new way to give the drug isatuximab for multiple myeloma that has returned or not responded to treatment. About 64 adults will receive isatuximab through a small device worn on the body, along with two other drugs. The goal is to see if this combination can shr…

This study looks at the long-term safety and effectiveness of a drug called lunsekimig in adults with chronic sinusitis and nasal polyps that are not well controlled. Participants must have completed a previous lunsekimig study and will receive the drug for about 52 weeks, with a…

This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine and help achieve remission. Participants will receive one o…

This study tests a new medicine called lunsekimig in adults aged 40-80 with COPD that is not well controlled, especially those with a type of inflammation called eosinophilic. The goal is to see if it can reduce the number of moderate-to-severe flare-ups and improve breathing ove…

This study tests an experimental drug called SAR444336 in 54 adults with microscopic colitis who are currently in remission using budesonide (a steroid). The goal is to see if the drug can keep them symptom-free without needing steroids for 24 weeks. Participants will receive eit…

This study tests a drug called belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The disease has not improved with at least two prior treatments. The goal is to find the right dose and see if t…

This study tests an injectable medicine called dupilumab in children aged 2 to under 6 years whose asthma or wheezing is not well controlled with standard inhalers. The goal is to see if it can reduce severe asthma attacks and improve breathing safety over a year. About 90 childr…

This study tests a medicine called duvakitug in people with moderate-to-severe Crohn's disease who already responded to it in an earlier study. The goal is to see if it can keep symptoms and gut inflammation under control for up to 5 years. About 671 adults will take either the d…

This study tests whether dupilumab, an injectable drug, can reduce mucus blockages in the lungs of people with moderate-to-severe COPD. About 218 participants aged 40-85 who smoke or used to smoke will receive either dupilumab or a placebo for 24 weeks. The goal is to see if the …

This study tests if a monthly shot of frexalimab works as well as the IV version for adults with multiple sclerosis. About 160 people aged 18-60 will take part. The goal is to see if the shot is safe and keeps the disease under control, offering a more convenient option.

This study follows 200 people with stage 2 type 1 diabetes who are taking TZIELD, a drug that delays the disease from getting worse. The goal is to monitor long-term side effects like infections or allergic reactions. Participants are treated as part of their normal care, and res…

This study is for children aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that causes joint swelling and fevers. The purpose is to find the best dose of the drug sarilumab, which helps control inflammation. Researchers will m…

This study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if it helps control blood sugar and reduces the need for insulin at mealtimes. Participants receive either teplizumab or a placebo by IV, and rese…

This study tests a new gene therapy called SAR446268 for people aged 10 to 55 with myotonic dystrophy type 1, a genetic muscle disease. The therapy aims to reduce harmful RNA levels and improve muscle function. The trial has two parts: first, finding the safest dose, then testing…

This study tests a new medicine called duvakitug for people with moderate to severe Crohn's disease. About 980 adults will receive either the drug or a placebo for 12 weeks to see if it reduces symptoms and heals the gut lining. The goal is to find a better treatment option for t…

This early-stage study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose, and then comparing two dose schedules to se…

This study tests a single injection of SAR402663 into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it is safe and can reduce the need for repeated standard treatments. About 66 adults aged 50-90 who have…

This study tests an experimental drug called rilzabrutinib against a placebo in 124 adults with active IgG4-related disease, a rare condition causing painful swelling in organs. The goal is to see if the drug can prevent disease flares and reduce the need for steroids over 52 wee…

This early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and …

This study tests an experimental drug called SAR442970 in 99 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo for 16 weeks, followed by a long-term extension where everyone can get the drug. The goal is to see if the drug can re…

This study tests a new drug called brivekimig for people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 208 adults will receive either brivekimig or a placebo to see if it reduces skin abscesses and inflammation. The goal i…

This study tests a new drug called itepekimab for adults with chronic sinusitis and nasal polyps that are not well controlled with standard sprays. About 210 participants will receive either the drug or a placebo for 52 weeks, alongside their usual nasal spray. The goal is to see…

This study looks at the long-term safety and effectiveness of a drug called lunsekimig for adults with asthma. Participants who finished a previous study can join this one and receive the drug for up to 96 weeks. The goal is to see if the drug continues to help control asthma and…

This study tests a new vaccine (PCV21) in healthy infants to see if it safely helps their bodies build defenses against 21 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. About 2,195 babies will receive four doses of either the ne…

This study is a safety check for Beyfortus, a medicine given to children up to 24 months old to prevent RSV, a serious lung infection. Researchers will watch 3,000 children in Korea for 180 days after they get the drug to see if any side effects occur. The goal is to make sure th…

This study tests a drug called dupilumab in 18 children and teens (6 months to under 18 years) with prurigo nodularis, a skin condition causing very itchy bumps. The main goal is to see how the drug moves through the body and if it is safe. Participants receive the drug for 24 we…

This study tests a drug called itepekimab in adults with chronic sinusitis and nasal polyps that are not well controlled by standard treatments. About 210 participants will receive either the drug or a placebo for up to 52 weeks, alongside their usual nasal spray. The goal is to …

This study tests a drug called dupilumab for adults with severe, long-term itching that has no known cause. About 284 people aged 18 to 90 will receive either dupilumab or a placebo for 24 weeks, along with standard itch treatments. The goal is to see if dupilumab can safely redu…

This study is testing whether dupilumab, a medication already used for moderate-to-severe atopic dermatitis (eczema), can also help reduce anxiety and depression symptoms. About 184 participants in Gulf countries who have eczema and signs of anxiety or depression will be observed…

This study follows 550 people with stage 2 type 1 diabetes in the U.S. to see how teplizumab treatment affects their quality of life, anxiety, and diabetes burden. Some participants received teplizumab, others did not. Researchers will compare the two groups to understand real-wo…

This study follows up to 10 children under 2 years old who are already receiving olipudase alfa for acid sphingomyelinase deficiency (ASMD). The goal is to monitor long-term safety and whether the body develops antibodies against the drug. No new treatment is given; researchers s…

This study follows 150 adults with eosinophilic esophagitis (EoE) who are starting dupilumab as part of their normal care. Researchers will collect information on medical history, symptoms, quality of life, and any side effects over two years. The goal is to understand how well d…

This study aims to describe the characteristics, treatment burden, and quality of life of 2,500 people with asthma across different severity levels. It includes a one-time assessment and a follow-up to track changes over time. No new treatments are tested; the goal is to gather r…

This study follows 400 people with chronic spontaneous urticaria (long-lasting hives) who are already prescribed dupilumab by their doctor. Researchers will collect information from medical records and patient surveys over 24 months to see how well the drug works in real life, it…

This study screens children and teenagers (ages 1.5 to 18) who have a parent or sibling with type 1 diabetes. The goal is to find early signs of the disease, like specific antibodies in the blood, before any symptoms appear. Participants will have two visits over 13 months to che…

This study collects information from medical records of 60 people with stage 2 type 1 diabetes who received the drug teplizumab through special access programs. The goal is to describe their characteristics, such as age and family history, and track how their diabetes progresses …

This study collects safety information from about 100 women with Pompe disease who received the drug Nexviazyme during pregnancy or breastfeeding, and from their babies. Researchers will track pregnancy complications, birth outcomes, and infant growth and development through the …

This study will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments are used, how well they work, and how the disease changes over 5 years. The goal is to better understand patien…

This study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their regular care. Researchers will track symptoms, quality of life, and disease control over two years using questionnaires and checkups. The goal is to understand…

This study checks whether a single dose of the experimental drug balinatunfib changes the heart's electrical activity in 44 healthy adults aged 18 to 55. Participants will receive the drug, a placebo, and another control drug in random order. The goal is to ensure the drug is saf…

This study watches how French doctors manage moderate-to-severe atopic dermatitis (eczema) in adults who need strong medications. It will follow 600 patients for one year to see which treatments are used, how long they work, and how well patients stick with them. No new treatment…

This study follows about 500 adults with uncontrolled COPD who are taking dupilumab as part of their regular care. Researchers will collect data over 36 months to understand patient characteristics, safety, and how the drug affects symptoms and flare-ups. The goal is to learn mor…

This study looks at over 500,000 health records to see if doctors' diagnosis codes accurately identify chlamydia infections. Researchers will compare these codes with lab test results to find the best way to spot cases. The goal is to make sure future chlamydia vaccine studies us…